Wilopo, Bayu A. P.
Richardson, Malcolm D.
Denning, David W.
Funding for this research was provided by:
University of Manchester
Article History
First Online: 25 November 2019
Compliance with Ethical Standards
:
: David W. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Zambon, iCo Therapeutics, Roivant, Biosergen and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and the British Society for Medical Mycology Standards of Care committee. Malcolm D. Richardson has received personal fees for talks and consultancy from Gilead Sciences Europe, Pfizer, MSD and Basilea, Dynamiker, Mylan and Lupin Pharmaceuticals. He is currently a member of the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis and Rare Moulds Guidelines groups. Bayu Wilopo declares no conflicts of interest relevant to this manuscript.
: This article does not contain any studies with human or animal subjects performed by any of the authors.